What Spazmotek Plus Treats: Main Uses and Benefits

Spazmotek Plus is commonly used to help with symptomatic relief by addressing symptom clusters that may become intense or disruptive, particularly those arising from heightened physiological activity. It offers supportive therapeutic benefit in clinical settings that involve acute or unstable symptom patterns. The therapeutic benefit is considered relevant for managing spasm of the gastro-intestinal or genito-urinary tract.

It is applied across domains where additional symptomatic support is needed, including conditions involving episodic or fluctuating manifestations, such as symptoms linked to organ-specific functional stress.

“It provides support that helps ease the overall symptom burden, relevant when symptoms become temporarily overwhelming.”

The medication is often used when symptoms intensify and supportive relief is needed for acute episodes of pronounced discomfort or visceral pain, contributing to improved comfort during periods of heightened symptoms. It helps address symptom clusters that may appear suddenly or fluctuate, supporting patients during episodes of heightened discomfort.

---

Quick Fact: Supportive Symptomatic Relief

It is commonly used across conditions presenting with acute episodes, and may be part of symptomatic management for functional abdominal disorders, providing supportive relief when symptoms interfere with routine activities.

Official Population Eligibility and Restrictions

Spazmotek Plus is strictly contraindicated for several populations according to regulatory labeling. Absolute prohibitions include known hypersensitivity to Acetaminophen, Hyoscine Butylbromide, or excipients, severe hepatocellular insufficiency or severe active liver disease, and myasthenia gravis. Due to the antispasmodic component, the medicine must not be used by patients with untreated narrow-angle glaucoma, megacolon, paralytic or obstructive ileus, or mechanical stenosis in the gastrointestinal tract.

Restricted and Not Recommended Populations

Use is not recommended during pregnancy or lactation due to insufficient data to establish safety for the fixed-dose combination. The medicine is generally not suitable for children under 10 years of age. Caution is required for patients with severe renal impairment, existing hepatic impairment (not severe), and those susceptible to urinary retention or tachyarrhythmia. Older adults must use the medicine with caution due to increased susceptibility to anticholinergic effects.

Interactions with other medicines and products

The interaction profile for Spazmotek Plus is defined by the distinct actions of its two components: Acetaminophen and Hyoscine Butylbromide. All interaction patterns are documented in regulatory sources.

Interaction-Related Restrictions

Co-administration with other Acetaminophen-containing products (prescription or nonprescription) is prohibited to prevent exceeding the maximum daily dose and the risk of severe hepatotoxicity. Chronic excessive consumption of alcohol is also documented as a risk factor that increases the potential for Acetaminophen-induced hepatotoxicity.

Documented Drug-Drug Interaction Outcomes

Interacting Substance/Class	Official Interaction Outcome
Anticholinergics (e.g., Tricyclic Antidepressants, Antihistamines)	Anticholinergic effects may be intensified by the Hyoscine Butylbromide component (additive pharmacodynamic effect).
Dopamine Antagonists (e.g., Metoclopramide)	May result in diminution of the effects of both drugs on gastrointestinal motility (pharmacodynamic antagonism).
Probenecid	Reduces the clearance of Acetaminophen, requiring a formal Paracetamol dose reduction during concurrent use.
Cholestyramine	Reduces the absorption of the Acetaminophen component.
Hepatic Enzyme Inducers (e.g., Glutethimide)	Increases the risk of Acetaminophen hepatotoxicity due to enhanced metabolic activation.

Population-Specific Consideration

Use of the Acetaminophen component for long periods in patients taking oral anti-coagulants (e.g., Warfarin) is only advisable under medical supervision due to the potential for an increase in International Normalized Ratio (INR).

Spazmotek Plus functions primarily by targeting the voltage-gated L-type calcium channels found in smooth muscle cells, particularly those lining the gastrointestinal tract and the genitourinary system. The active ingredient binds to a specific allosteric site on the alpha1 subunit of these channels.

This interaction constitutes a non-competitive modulation that significantly reduces the influx of extracellular calcium ions (Ca^2+) into the myocyte cytoplasm. The resulting decrease in intracellular Ca^2+ concentration limits the activation of the calcium-calmodulin complex and subsequently inhibits the activity of myosin light-chain kinase (MLCK).

Inhibition of MLCK prevents the phosphorylation of the myosin head. The unphosphorylated myosin cannot properly interact with actin filaments, thus suppressing the fundamental contractile mechanism. This molecular cascade ultimately leads to relaxation of the smooth muscle tissue, resulting in a systemic antispasmodic effect across affected organ systems.

How to Use Spazmotek Plus

Spazmotek Plus is a fixed-dose combination product containing Hyoscine Butylbromide (10 mg) and Paracetamol (500 mg). The administration guidelines define its usage as a structured, short-term protocol.

---

Administration Guidelines

Category	Instruction Principle
Route & Form	The medicine is for oral administration only as a film-coated tablet.
Standard Adult Dose	The standard dose for adults is 1 to 2 tablets per administration.
Frequency & Limits	It may be taken up to 3 times daily, but the total daily dose must not exceed 6 tablets.
Course Duration	Use is limited to short-term symptomatic management, typically not for more than 3 consecutive days without medical guidance.

---

Procedural and Population Requirements

Tablets must be swallowed whole with an adequate amount of water and should not be crushed or chewed. The medicine may be taken with or without food. Due to the paracetamol component, concurrent use of any other paracetamol-containing products is restricted to ensure the maximum total daily dose is not exceeded.

Specific dosage principles exist for certain populations. The medicine is not suitable for children under 10 years of age. For patients with impaired hepatic or renal function, the dose or the time interval between doses may need adjustment. If a dose is forgotten, a double dose should not be taken to compensate.

Research evidence / Overview of Studies for Spazmotek Plus

Evidence for Recurrent Crampy Abdominal Pain

The research base includes short-term, randomized controlled trials (RCTs) examining the fixed-dose combination in adults experiencing recurrent colic-type abdominal pain. These trials, typically lasting 3 to 4 weeks, were designed to measure physical discomfort, including patient-reported change in pain intensity. Findings describe patterns where lower reported pain scores were recorded compared to placebo. Research also examined the combination against the single active components, where the measured difference in outcomes was often small or varied.

Evidence for Painful Menstruation (Dysmenorrhea)

Research exploring this product in the context of painful menstruation includes acute-setting RCTs and large-scale observational studies focused on adult women. Outcomes monitored included change in cramps and pain intensity and measures of daily activity level. The evidence level is moderate, but research limitations include self-reporting and selection biases inherent in observational studies.

Evidence for Non-Specific Acute Colicky Pain

The fixed-dose product was evaluated in a research structure that includes acute-care RCTs examining children and adolescents (aged 8–17 years). These studies monitored the change in pain score and the need for rescue pain medication during periods of increased symptom activity. Comparative evidence is lacking for the specific fixed-dose combination, and follow-up durations were limited to immediate, short-term outcomes.

Long-Term Follow-up Data and Research Gaps

The research base includes studies designed to evaluate short-term symptom patterns, with follow-up durations typically limited to a few weeks. There is limited information for long-term outcomes regarding use over sustained periods. Researchers report that data for older adults and patients with specific comorbidities remain limited, and certainty remains low regarding long-term outcomes and use outside of the defined study populations.

Key Studies & References World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) Index: Acetaminophen (N02BE01)

Common questions about Spazmotek Plus (FAQ)

Q: What makes the 'Plus' version different from the regular Spazmotek?

According to official product information, the 'Plus' formulation is a fixed-dose combination product.

It contains two active ingredients: the antispasmodic component, Hyoscine Butylbromide, and the analgesic component, Paracetamol (Acetaminophen). This dual-ingredient composition is noted to differentiate it from the single-component formulation.

Q: Are there any known issues with taking Spazmotek Plus and driving?

Official regulatory documents advise that this medicine may cause sight issues, such as blurred vision, or may cause drowsiness.

Regulatory documents indicate that if these effects occur, driving or operating machinery is not advised until the symptoms have fully resolved.

Q: Can Spazmotek Plus affect my blood pressure readings?

The product label lists tachycardia (increased heart rate) as a possible adverse reaction related to the anticholinergic component.

Official warnings also cite unexplained abdominal pain occurring together with reduced blood pressure as a specific symptom that requires seeking immediate medical advice.

Q: Are there any specific foods that interact with Spazmotek Plus?

Chronic, excessive consumption of alcohol is the primary caution noted in regulatory documents, as it increases the risk of severe liver damage from the Acetaminophen component.

No specific food items other than alcohol are commonly listed in authoritative sources as major interactors that pose a risk.

Q: What are the main reasons someone might need to stop using Spazmotek Plus?

Regulatory documents state that use of the product must be discontinued immediately if symptoms of a severe allergic reaction develop, or if serious blistering skin conditions (such as Stevens-Johnson Syndrome) are suspected.

Additionally, the medicine must be stopped if severe unexplained abdominal pain persists, worsens, or occurs alongside symptoms like fever or vomiting.

Q: What is the regulatory guidance for using Spazmotek Plus in people with kidney problems?

The official product information indicates that the time interval between individual administrations may need adjustment for individuals with impaired renal function.

It also notes that the medicine requires caution in cases of severe renal impairment.

Q: What if I take an over-the-counter cold medicine with Spazmotek Plus?

Co-administration with any other product containing Paracetamol (Acetaminophen), including many non-prescription cold and flu remedies, is restricted in regulatory guidelines.

This is to prevent exceeding the maximum daily dose for Acetaminophen and risking severe hepatic (liver) injury.

Q: Are there different strengths of Spazmotek Plus available?

Spazmotek Plus is officially defined and referenced as a fixed-dose combination product containing 10 mg of Hyoscine Butylbromide and 500 mg of Paracetamol per tablet.

Regulatory labeling generally only references this single combination strength.

Q: Is the 'Plus' ingredient intended to enhance the main component?

Official product information states that the medicine is designed to provide a dual action for symptomatic relief.

Specifically, the antispasmodic component (Hyoscine Butylbromide) helps relieve muscle spasm, while the analgesic component (Paracetamol) relieves pain, addressing two distinct aspects of discomfort simultaneously.

Q: What is the risk of overdose with Spazmotek Plus?

Taking a dose exceeding the regulatory limit can lead to serious health consequences, particularly the risk of severe hepatic injury (acute liver failure) due to the Paracetamol component.

Regulatory guidelines indicate that immediate medical attention is necessary if an overdose is suspected.

Q: How quickly does Spazmotek Plus typically start working?

While specific onset times are not provided, regulatory documents note that the absorption rate of the Paracetamol component may be reduced if gastric emptying is slowed down by other substances.

This reduction in absorption could potentially lead to a delayed onset of the product's pain-relieving action.

Q: Do I need to change my diet while taking Spazmotek Plus?

Regulatory documents do not mandate any general dietary changes while using the medicine.

However, chronic, excessive consumption of alcohol is strongly addressed in regulatory documents as a risk factor for liver damage.

Q: Is it common to feel tired after starting Spazmotek Plus?

Although general tiredness is not typically listed, the official label mentions drowsiness as a possible side effect related to the Hyoscine Butylbromide component.

The presence of drowsiness is noted in the labeling as a symptom that requires caution.

Q: Can I take Spazmotek Plus with my multivitamin?

Regulators generally advise patients to inform a healthcare provider or pharmacist about all other products they are taking, including vitamins and herbal supplements.

Since these products are not routinely tested for their interaction with prescription medicines, sharing this information is important to share with a healthcare provider.

Q: Is Spazmotek Plus considered an opioid or a controlled substance?

The medicine is classified as a combined analgesic (non-opioid) and antispasmodic agent.

It contains Paracetamol (Acetaminophen) and Hyoscine Butylbromide, neither of which are opioids nor generally listed as controlled substances.

Q: Is Spazmotek Plus used for anxiety or sleep issues?

The licensed indication for this product is the symptomatic relief of pain and spasm associated with specific conditions, such as gastrointestinal cramps and dysmenorrhea.

It is not licensed for the treatment of anxiety or sleep issues.

Q: How is Spazmotek Plus eliminated from the body?

Pharmacokinetic data from regulatory sources indicate that after oral administration, the majority of the recovered radioactivity (approximately 90%) is eliminated from the body via the faeces.

A small percentage of the dose is also excreted through the urine.

Q: Is it okay to drink coffee while taking Spazmotek Plus?

Regulatory documents do not specifically mention an interaction with coffee or caffeine.

However, general regulatory advice emphasizes caution when co-administering any medicines, vitamins, or supplements, and consulting a healthcare provider about this is a recommended general practice.

Q: How long do the effects of Spazmotek Plus usually last?

Regulatory pharmacokinetic data provides the terminal elimination half-life for the active ingredient, Hyoscine Butylbromide.

This half-life following oral administration has been reported to range from 6.2 to 10.6 hours.

Q: Can taking Spazmotek Plus affect fertility or reproductive health?

Official regulatory documents and related sources state that there is no evidence to suggest the active ingredient, Hyoscine Butylbromide, affects fertility in men or women.

Q: Is there a link between Spazmotek Plus and stomach irritation?

General gastrointestinal (GI) irritation is listed in adverse reaction profiles as a possible, non-frequent effect.

It is not cited as a common or major warning in regulatory documents.

Q: Can Spazmotek Plus interact with herbal supplements like St. John's Wort?

The regulatory guidance highlights the need for consultation with a healthcare professional regarding herbal remedies or supplements, including products like St. John's Wort.

This is because there is often insufficient information to state that all complementary medicines are safe to take alongside the product.

Q: Does Spazmotek Plus contain a sulfa drug or any common allergens?

The medicine is noted to not contain a sulfa drug.

Detailed excipient (inactive ingredients) lists are officially published, and the medicine is strictly contraindicated for individuals with known hypersensitivity to the active ingredients or any of the listed excipients.

Q: Are there any specific lab tests needed while using Spazmotek Plus?

Routine monitoring with specific lab tests is not typically required by regulators.

However, it is advised that blood count and renal (kidney) and liver function should be monitored after prolonged use, particularly in certain populations.

Q: Does Spazmotek Plus have a potential for dependence or misuse?

As a non-opioid, non-scheduled antispasmodic and analgesic combination, the product is not associated with a potential for dependence or misuse according to its classification and official safety profile.

Q: Can I take Spazmotek Plus if I am lactose intolerant?

The product's inactive ingredient list often includes lactose monohydrate.

Regulatory documents require a specific warning for patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.

How to Store and Dispose of Spazmotek Plus?

This medicine must be stored according to official regulatory requirements to maintain its stability until the expiration date.

Storage Conditions

Spazmotek Plus should be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in a cool, dry place and protected from light and excessive heat. To maintain stability, the tablets must remain in their original pack until needed, and they should not be used past the expiration date on the carton.

Child Safety and Disposal

The most important safety requirement is to store this medicine out of the sight and reach of children.

For disposal, official guidance states that unused or expired tablets must not be thrown away in household waste or flushed down wastewater. Patients should follow local regulations for pharmaceutical waste or consult a pharmacist for instructions on proper disposal.